Daré Bioscience, Inc. (DARE)
0.7291
-0.01
(-1.30%)
USD |
NASDAQ |
Aug 28, 11:59
Daré Bioscience Cash from Operations (Quarterly) : -6.775M for June 30, 2026
Cash from Operations (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.775M |
| March 31, 2026 | -5.521M |
| December 31, 2025 | 1.444M |
| September 30, 2025 | -0.4421M |
| June 30, 2025 | -5.418M |
| March 31, 2025 | -5.470M |
| September 30, 2024 | -5.924M |
| June 30, 2024 | 12.91M |
| March 31, 2024 | -6.821M |
| December 31, 2023 | -8.179M |
| September 30, 2023 | -7.974M |
| June 30, 2023 | -6.586M |
| March 31, 2023 | -16.12M |
| December 31, 2022 | -5.897M |
| September 30, 2022 | 8.600M |
| June 30, 2022 | -8.448M |
| March 31, 2022 | -12.34M |
| December 31, 2021 | -9.916M |
| September 30, 2021 | 1.320M |
| June 30, 2021 | -11.79M |
| March 31, 2021 | -8.377M |
| December 31, 2020 | -9.194M |
| September 30, 2020 | -5.357M |
| June 30, 2020 | -4.087M |
| March 31, 2020 | -6.598M |
| Date | Value |
|---|---|
| December 31, 2019 | -3.809M |
| September 30, 2019 | -3.180M |
| June 30, 2019 | -3.018M |
| March 31, 2019 | -3.308M |
| December 31, 2018 | -2.710M |
| September 30, 2018 | -2.750M |
| June 30, 2018 | -2.689M |
| March 31, 2018 | -2.119M |
| December 31, 2017 | -0.9611M |
| September 30, 2017 | -1.419M |
| June 30, 2017 | -0.1096M |
| March 31, 2017 | -0.0506M |
| December 31, 2016 | -1.875M |
| September 30, 2016 | -7.16M |
| June 30, 2016 | -11.24M |
| March 31, 2016 | -13.26M |
| December 31, 2015 | -8.21M |
| September 30, 2015 | -7.967M |
| June 30, 2015 | -7.797M |
| March 31, 2015 | -7.941M |
| December 31, 2014 | -5.608M |
| September 30, 2014 | -5.558M |
| June 30, 2014 | -4.229M |
| March 31, 2014 | -3.666M |
| December 31, 2013 | -3.271M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Nektar Therapeutics | -75.77M |
| Elite Pharmaceuticals, Inc. | 10.07M |
| Eton Pharmaceuticals, Inc. | 7.255M |
| ANI Pharmaceuticals, Inc. | 56.67M |
| Corcept Therapeutics, Inc. | 33.54M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -0.0806M |
| Cash from Financing (Quarterly) | 0.9512M |
| Free Cash Flow | -11.76M |
| Free Cash Flow Per Share (Quarterly) | -0.4604 |
| Free Cash Flow to Equity (Quarterly) | -6.436M |
| Free Cash Flow to Firm (Quarterly) | -6.665M |
| Free Cash Flow Yield | -113.8% |